Medicament intended for oral administration and which' has improved bioavailability, said medicament comprising an agglomerate based on inert sold particles having a base of at least one excipient, said agglomerate comprising a cyclo-oxygenase-2 inhibitor and at least one hydrophilic polymer, characterised in that said agglomerate comprises the product of spraying a solution or suspension of micronised grains of said inhibitor in said polymer(s) onto said particles to agglomerate said particles, and in that said inhibitor is made up of at least one compound based on formula or a salt or a solvate of this compound: where: one of the elements X and Y represents N and the other represents C; R1 represents a hydrogen, methyl, halogen, cyano, nitro, -CHO, -COCH 3 or -COOR 4 group; R2 represents an aryl or heteroaryl group optionally substituted by one or more groups chosen independently from the halogen, C 1-8 alkyl, C 1-8 haloalkyl, R 4 OC 0-8 alkyl, R 4 SC 0-8 alkyl, cyano, nitro, -NR 4 R 6, -NR 4 SO 2 R 5, -SOR 5, -SO 2 R 5, -SO 2 NR 4 R 6 or -CONR 4 R 6 groups; R3 represents a C 1-8 alkyl, C 1-8 haloalkyl or NR 4 R 6 group; R4 represents a hydrogen, C 1-8 alkyl or C 0-8 alkyl aryl group (where the aryl group may optionally be substituted by one or more groups chosen from the C 1-8 alkyl, halogen, C 1-8 haloalkyl, cyano, nitro, R 7 OC 0-8 alkyl, R 7 SC 0-8 alkyl, -NR 7 R 8, -NR 7 COR 5, -COR 7 or -COOR 7 groups); R5 represents a C 1-8 alkyl or C 1-8 haloalkyl group; R6 represents a hydrogen, C 1-8 alkyl, C 1-8 aryl alkyl group (where the aryl group may optionally be substituted by one or more groups chosen from the C 1-8 alkyl, halogen, C 1-8 haloalkyl, cyano, nitro, R 7 OC 0-8 alkyl, R 7 SC 0-8 alkyl, -NR 7 R 8, -NR 7 COR 5, -COR 7 or -COOR 7 groups), -COR 8 or -COOR 8 group; R7 represents a hydrogen, C 1-8 alkyl or benzyl group; R8 represents a C 1-8 alkyl or C 1-8 haloalkyl group; the aryl group in the definitions above representing a phenyl or naphthyl group; and the heteroaryl group in the definitions above represents a pyridine, pyrazine, pyrimidine or pyridazine group, which may optionally be fused to a benzene ring, said medicament further being characterised in that said agglomerate comprises said hydrophilic polymer(s) in a fraction by weight ranging from 12% to 25 %. one of the elements X and Y represents N and the other represents C; R1 represents a hydrogen, methyl, halogen, cyano, nitro, -CHO, -COCH 3 or -COOR 4 group; R2 represents an aryl or heteroaryl group optionally substituted by one or more groups chosen independently from the halogen, C 1-8 alkyl, C 1-8 haloalkyl, R 4 OC 0-8 alkyl, R 4 SC 0-8 alkyl, cyano, nitro, -NR 4 R 6, -NR 4 SO 2 R 5, -SOR 5, -SO 2 R 5, -SO 2 NR 4 R 6 or -CONR 4 R 6 groups; R3 represents a C 1-8 alkyl, C 1-8 haloalkyl or NR 4 R 6 group; R4 represents a hydrogen, C 1-8 alkyl or C 0-8 alkyl aryl group (where the aryl group may optionally be substituted by one or more groups chosen from the C 1-8 alkyl, halogen, C 1-8 haloalkyl, cyano, nitro, R 7 OC 0-8 alkyl, R 7 SC 0-8 alkyl, -NR 7 R 8, -NR 7 COR 5, -COR 7 or -COOR 7 groups); R5 represents a C 1-8 alkyl or C 1-8 haloalkyl group; R6 represents a hydrogen, C 1-8 alkyl, C 1-8 aryl alkyl group (where the aryl group may optionally be substituted by one or more groups chosen from the C 1-8 alkyl, halogen, C 1-8 haloalkyl, cyano, nitro, R 7 OC 0-8 alkyl, R 7 SC 0-8 alkyl, -NR 7 R 8, -NR 7 COR 5, -COR 7 or -COOR 7 groups), -COR 8 or -COOR 8 group; R7 represents a hydrogen, C 1-8 alkyl or benzyl group; R8 represents a C 1-8 alkyl or C 1-8 haloalkyl group; the aryl group in the definitions above representing a phenyl or naphthyl group; and the heteroaryl group in the definitions above represents a pyridine, pyrazine, pyrimidine or pyridazine group, which may optionally be fused to a benzene ring, said medicament further being characterised in that said agglomerate comprises said hydrophilic polymer(s) in a fraction by weight ranging from 12% to 25 %.